Michele Redell

List of Publications by Year
in descending order

57 papers	1,042 citations	516710 16 h-index	434195 31 g-index
58 all docs	58 docs citations	58 times ranked	1878 citing authors

#	Article	IF	Citations
1	Targeting signaling pathways vulnerabilities for the treatment of IKZF1-deleted ph-negative B lymphoblastic leukemia.. Journal of Clinical Oncology, 2022, 40, 7033-7033.	1.6	1
2	Aberrantly low STAT3 and STAT5 responses are associated with poor outcome and an inflammatory gene expression signature in pediatric acute myeloid leukemia. Clinical and Translational Oncology, 2021, 23, 2141-2154.	2.4	5
3	Introduction to the Special Issue on Pediatric Acute Myeloid Leukemia: Current Management and Future Directions. Children, 2021, 8, 698.	1.5	0
4	Cite-Seq Reveals Distinct Patterns and Potential Mechanisms of Relapse in Pediatric AML. Blood, 2021, 138, 3458-3458.	1.4	0
5	Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Collaboration. Blood, 2021, 138, 1247-1247.	1.4	3
6	Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Cancers, 2021, 13, 6263.	3.7	7
7	Pediatric myeloid sarcoma: a single institution clinicopathologic and molecular analysis. Pediatric Hematology and Oncology, 2020, 37, 76-89.	0.8	20
8	Modulating TNFÎ± activity allows transgenic IL15-Expressing CLL-1 CAR T cells to safely eliminate acute myeloid leukemia. , 2020, 8, e001229.		29
9	Targeting STAT3 anti-apoptosis pathways with organic and hybrid organicâ€“inorganic inhibitors. Organic and Biomolecular Chemistry, 2020, 18, 3288-3296.	2.8	8
10	Comparison of the Transcriptomic Signatures in Pediatric and Adult CML. Blood, 2020, 136, 39-40.	1.4	1
11	Drug targeting of NR4A nuclear receptors for treatment of acute myeloid leukemia. Leukemia, 2019, 33, 52-63.	7.2	28
12	Management of chronic myeloid leukemia in children and adolescents: Recommendations from the Children's Oncology Group CML Working Group. Pediatric Blood and Cancer, 2019, 66, e27827.	1.5	50
13	Atovaquone is active against AML by upregulating the integrated stress pathway and suppressing oxidative phosphorylation. Blood Advances, 2019, 3, 4215-4227.	5.2	34
14	Enhancing the Effect of CLL-1 CAR T Cells with Interleukin-15 for Treatment of Acute Myeloid Leukemia. Blood, 2019, 134, 3912-3912.	1.4	2
15	Targeting Activated Signaling Pathways for the Treatment of IKZF1-Deleted B Lymphoblastic Leukemia. Blood, 2019, 134, 3789-3789.	1.4	2
16	Inhibition of BMP-Smad Pathway Reduces Leukemic Stemness in Pediatric AML. Blood, 2019, 134, 3731-3731.	1.4	1
17	Comparision of four and six color multiparametric flow cytometry panels to diagnose pediatric leukemias. Annals of Global Health, 2018, 82, 440.	2.0	0
18	Glucocorticoids Inhibit Oncogenic RUNX1-ETO in Acute Myeloid Leukemia with Chromosome Translocation t(8;21). Theranostics, 2018, 8, 2189-2201.	10.0	9

#	Article	IF	Citations
19	Comparison of the Transcriptomic Signature of Pediatric Vs. Adult CML and Normal Bone Marrow Stem Cells. Blood, 2018, 132, 4246-4246.	1.4	5
20	Signaling Responses to Stroma-Derived Soluble Factors Are Associated with Outcome and with Expression of Microenvironment-Related Genes in Pediatric AML. Blood, 2018, 132, 1510-1510.	1.4	0
21	Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance. Blood Advances, 2017, 1, 1387-1397.	5.2	55
22	Distinct signaling events promote resistance to mitoxantrone and etoposide in pediatric AML: a Childrenâ€™s Oncology Group report. Oncotarget, 2017, 8, 90037-90049.	1.8	5
23	CD123-Engager T Cells as a Novel Immunotherapeutic for Acute Myeloid Leukemia. Molecular Therapy, 2016, 24, 1615-1626.	8.2	70
24	A STAT3 decoy lures AML out of hiding. Blood, 2016, 127, 1628-1629.	1.4	5
25	Assessing the intracellular fate of rhodium(<scp>ii</scp>) complexes. Chemical Communications, 2016, 52, 11685-11688.	4.1	17
26	Pharmacological inhibition of LSD1 for the treatment of MLL-rearranged leukemia. Journal of Hematology and Oncology, 2016, 9, 24.	17.0	90
27	Differential Expression of Adhesion Molecule Receptors May Influence Bone Marrow Microenvironment-Mediated Protection of Leukemia-Initiating Cells (LICs) in Infant MLL-rearranged (MLL-R) Acute Lymphoblastic Leukemia (ALL). Blood, 2016, 128, 1585-1585.	1.4	0
28	Rapid Infusion of Rituximab Is Well Tolerated in Children with Hematologic, Oncologic, and Rheumatologic Disorders. Blood, 2016, 128, 2329-2329.	1.4	0
29	The Bone Marrow Environment Promotes Resistance to Mitoxantrone and Etoposide By Distinct Mechanisms in Pediatric AML. Blood, 2016, 128, 3943-3943.	1.4	0
30	Interleukin-6 Levels Predict Relapse Free Survival in Pediatric AML and Suggest a Mechanism of Chemotherapy Resistance. Blood, 2016, 128, 1724-1724.	1.4	0
31	Adoptive immunotherapy for AML with CD123-engager T cells. , 2015, 3, .		0
32	Stromal <scp>CYR</scp>61 Confers Resistance to Mitoxantrone via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukaemia. British Journal of Haematology, 2015, 170, 704-718.	2.5	27
33	Rhodium(II) Proximityâ€Labeling Identifies a Novel Target Site on STAT3 for Inhibitors with Potent Antiâ€Leukemia Activity. Angewandte Chemie - International Edition, 2015, 54, 13085-13089.	13.8	31
34	Ligand-induced STAT3 signaling increases at relapse and is associated with outcome in pediatric acute myeloid leukemia: a report from the Children's Oncology Group. Haematologica, 2015, 100, e496-e500.	3.5	3
35	Adult Low-Hypodiploid Acute B-Lymphoblastic Leukemia With<i>IKZF3</i>Deletion and<i>TP53</i>Mutation. American Journal of Clinical Pathology, 2015, 144, 263-270.	0.7	10
36	Poorer Relapse-Free Survival in Hispanic Children Diagnosed with Acute Myeloid Leukemia Compared with Non-Hispanics: A Texas Single Institution Experience. Blood, 2015, 126, 1312-1312.	1.4	2

#	Article	IF	Citations
37	A Novel STAT3 Inhibitor Has Potent Activity in Preclinical Models of Acute Myeloid Leukemia That Incorporate the Stromal Environment. Blood, 2015, 126, 569-569.	1.4	4
38	DOT1L Inhibition Sensitizes MLL-Rearranged AML to Chemotherapy. PLoS ONE, 2014, 9, e98270.	2.5	63
39	Cytogenetically cryptic and FISH-negative PML/RARA rearrangement in acute promyelocytic leukemia detected only by PCR: an exceedingly rare phenomenon. Cancer Genetics, 2014, 207, 48-49.	0.4	25
40	Stromal CYR61 Confers Resistance to Mitoxantrone Via Spleen Tyrosine Kinase Activation in Human Acute Myeloid Leukemia. Blood, 2014, 124, 2228-2228.	1.4	0
41	CD123-Engager T Cells As a Novel Immunotherapeutic for AML. Blood, 2014, 124, 3762-3762.	1.4	0
42	Synthesis, activity and metabolic stability of non-ribose containing inhibitors of histone methyltransferase DOT1L. MedChemComm, 2013, 4, 822.	3.4	31
43	FACS analysis of Stat3/5 signaling reveals sensitivity to G-CSF and IL-6 as a significant prognostic factor in pediatric AML: a Children's Oncology Group report. Blood, 2013, 121, 1083-1093.	1.4	29
44	Intestinal perforation after treatment of Burkitt's lymphoma: Case report and review of the literature. Journal of Pediatric Surgery, 2013, 48, 436-440.	1.6	11
45	Bone Marrow Stromal Cells Enhance DNA Damage Signaling Independent Of Stat3 Activation In Pediatric AML. Blood, 2013, 122, 2548-2548.	1.4	0
46	Increased Responsiveness to Ligand Stimulation of the STAT Pathway At Relapse in Acute Myelogenous Leukemia. Blood, 2012, 120, 3544-3544.	1.4	0
47	Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor. Blood, 2011, 117, 5701-5709.	1.4	198
48	FACS Analysis of Stat3/5 Signaling Reveals Ligand Sensitivity As a Significant Prognostic Factor in Pediatric AML: A Children's Oncology Group Report. Blood, 2011, 118, 938-938.	1.4	1
49	Stroma-Mediated Chemotherapy Resistance in Acute Myeloid Leukemia Cells. Blood, 2011, 118, 242-242.	1.4	1
50	Multiparameter FACS Analysis of G-CSF and IL-6 Signaling through Stat3 and Stat5 In Primary Pediatric AML Samples.. Blood, 2010, 116, 1051-1051.	1.4	1
51	Wild-Type and Mutant C-Kit Activation of Stat3Î± Contribute to Leukemogenesis through Distinct Effects on Myeloid Cell Proliferation and Resistance to Apoptosis. Blood, 2008, 112, 5317-5317.	1.4	0
52	Stat3Î² Promotes Basal Granulopoiesis and Inhibits Emergency Granulopoiesis, While Stat3Î± Inhibits Basal Granulopoiesis and Promotes Emergency Granulopoiesis. Blood, 2008, 112, 3871-3871.	1.4	0
53	Stat3 Isoforms, Î± and Î², Demonstrate Distinct Intracellular Dynamics with Prolonged Nuclear Retention of Stat3Î² Mapping to Its Unique C-terminal End. Journal of Biological Chemistry, 2007, 282, 34958-34967.	3.4	51
54	Conditional overexpression of Stat3Î± in differentiating myeloid cells results in neutrophil expansion and induces a distinct, antiapoptotic and pro-oncogenic gene expression pattern. Journal of Leukocyte Biology, 2007, 82, 975-985.	3.3	18

#	Article	IF	Citations
55	Overexpression of Stat3Î±, but Not StatÎ², in Myeloid Cells Results in Neutrophil Expansion through Reduced Apoptosis and Modulation of a Unique Set of Apoptosis Pathway Genes.. Blood, 2006, 108, 1147-1147.	1.4	0
56	Targeting Transcription Factors for Cancer Therapy. Current Pharmaceutical Design, 2005, 11, 2873-2887.	1.9	78
57	IL-10 and TNFÎ± are associated with decreased survival in low-risk pediatric acute myeloid leukemia; a childrenâ€™s oncology group report. Pediatric Hematology and Oncology, 0, , 1-12.	0.8	3